HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q® Cancer Assay in newly diagnosed lung...
Hence then, the article about volitionrx announces data showing the prognostic value of its nu q cancer test was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test )
Also on site :
- Running on empty: What’s driving Europe’s auto industry crisis?
- Nigeria: Tough Times Await Terrorists As Tinubu Adopts Tech-Driven Strategy to Tackle Insecurity
- India’s Fuel Consumption Slips Despite Record Crude Oil Imports